Biotech & Health Tech
The FDA wants to pull its approval of a drug. It’s not so easy.
The regulator says Tavneos was approved on the basis of manipulated study data. Should patients still have access to it?
The regulator says Tavneos was approved on the basis of manipulated study data. Should patients still have access to it?
This is a summary of the story. Read the full article at Ars Technica ↗